Clinical Trial Update: Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females [Phase 2]

View source ↗

Summary

Phase 2 safety and immunogenicity study of MEDI-517 (GSK 580299) with or without adjuvant in healthy adult females has completed. The trial evaluated safety and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• MEDI-517 (GSK 580299) (MEDI-517)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 2 | Status: COMPLETED